HI
PLX icon

Harbour Investments’s Protalix BioTherapeutics PLX Stock Holding History

Harbour Investments’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13K Buy
+6,000
New +$14.9K ﹤0.01% 3124
2021
Q4 		– Sell
-3,000
Closed -$4K – 3421
2021
Q3 		$4K Buy
+3,000
New +$4.56K ﹤0.01% 3090

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Harbour Investments's PLX Position: Q1 2026 in Review

Harbour Investments opened a new position in Protalix BioTherapeutics (PLX) in Q1 2026: 6,000 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #3124 among its holdings. This is a return to the name: Harbour Investments previously reported a position in PLX as recently as Q3 2021.

Harbour Investments first reported a position in PLX in Q3 2021 and has held it in 2 quarters since. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Harbour Investments held 6,000 shares of Protalix BioTherapeutics worth $13K as of Q1 2026.
  • Protalix BioTherapeutics was a new Harbour Investments position in Q1 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #3124 holding.
  • Harbour Investments first reported a position in Protalix BioTherapeutics in Q3 2021 and has held it in 2 quarters since.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.